Expression of ΔNp73 and TAp73α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3922-3927

  Liu, Stephanie Si ^a   Chan, Kelvin Yuen Kwong ^a   Cheung, Annie Nga Yin ^a   Liao, Xiao Yun ^a   Leung, Tsin Wah ^a   Ngan, Hextan Yuen Sheung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISOPROTEIN; PROTEIN P37; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP73 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; SURVIVAL RATE; TIME; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 33746104471     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2573     Document Type: Article

References (22)

1. Liu SS, Leung RCY, Chan KYK, et al. p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res 2004;10:3309-16.
2. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
3. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998;58:5061-5.
4. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
5. Moll UM, Erster S, Zaika A. p53, p63 and p73: solos, alliances and feuds among family members. Biochim Biophys Acta 2001;1552:47-59.
6. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002;2:605-15.
7. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-49.
8. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207.
9. Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene 2003;22:5686-93.
10. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the Delta Np73 isoform, allowing apoptosis to occur. Cell Death Differ 2004;11:685-7.
11. Rossi M, De Laurenzi V, Munarriz E, et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005;24:836-48.
12. Moll UM, Slade N. p63 and p73: Roles in development and tumor formation. Mol Cancer Res 2004;2:371 -86.
13. Uramoto H, Sugio K, Oyama T, et al. Expression of Delta Np73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004;10:6905-11.
14. Casciano I, Mazzocco K, Boni L, et al. Expression of Delta Np73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002;9:246-51.
15. Concin N, Becker K, Slade N, et al. Transdominant Delta TAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004;64:2449-60.
16. Zaika Al, Slade N, Erster SH, et al. Delta Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80.
17. Putzer BM, Tuve S, Tannapfel A, Stiewe T. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN′-p73 transcript. Cell Death Differ 2003;10:612-4.
18. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001;37:1104-10.
19. Grob TJ, Fey MF, Tobler A.The two faces of p73. Cell Death Differ 2002;9:229-30.
20. Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999;91:1154-8.
21. Muller M, Schilling T, Sayan AE, et al. TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
22. Tomkova K, Belkhiri A, El Rifai W, Zaika Al. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 2004:64:6390-3.